• Spago Nanomedical launched a fully pre-emptive rights issue expected to raise about SEK 16 million before costs, issuing 147,016,174 new shares at SEK 0.11 each.
• Each existing share carries one subscription right, with nine rights required to subscribe for two new shares; the record date is May 29, 2026.
• Subscription runs June 3-17, 2026; subscription rights are set to trade June 3-12, 2026.
• Major shareholders, board members, and management have committed to subscribe about SEK 10.4 million, covering 64.4% of the offer.
• Proceeds are earmarked to fund completion of the Phase I portion of the Tumorad-01 study for 177Lu-SN201, preparations for Phase IIa, and increased business development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.